BACKGROUND Papillary thyroid cancer (PTC), accounts for approximately 90% of all thyroid cancer cases, the underlying mechanism was unclear. LINC00623 was a new proved epigenetic modification(ac4C) gene. However, the study about the role of LINC00623 in pan cancer and thyroid cancer induced by estradiol (E2) have not yet been explored.
METHODS Pan-cancer analysis based on TCGA was carried out by Sanger box. Different gene expressions were analyzed by DESeq2 Package. Receiver-operating characteristic (ROC) curves were used to evaluate the diagnostic value of it for Pan cancer and THCA. Overall survival was calculated by the Kaplan–Meier univariate and cox multivariate analyses. In vitro, after knockdown of LINC00623, MTT/clone formation/Cell cycle and apoptosis were carried out. E2/ Bisphenol (BPA) stimulation and GSK inhibition experiment was carried out.
RESULTS LINC00623 play an important role in diagnosis and prognosis in pan cancer and THCA.LINC00623 is an important biological indicator of immune microenvironment and immune infiltrating cells in pan-cancer and THCA. We first verified that E2 and BPA could induce the expression of LINC00623 in PTC cell lines. In vitro experiments verified that LINC00623 significantly affected the biological process of PTC such as proliferation, cycle, and apoptosis. Mechanism exploration identified LINC00623 affected the epigenetics of PTC, namely H3K27me3 and H3K36me3 through PHF19. The LINC00623 promote the progress of BHP10-3 cell acting as an oncogene; LINC00623 knock down increased the H3K27me3 and down regulated the H3K27me3 via PHF19, GSK126 can rescue the cell biological inhibition caused by LINC00623 knock down.
Conclusion LINC00623 play a significant role in pan-cancer and thyroid cancer. E2/BPA can induce the expression of LINC00623.LINC00623 was an epigenetic regulator of H3K27me3 and H3K36me3 via PHF19 in PTC. It can be a potential therapy target for PTC.